Roche Pharma Unit Chief on Covid Tests, Alzheimer's Drug

The transcript covers Roche's business growth, focusing on R&D investments and COVID-19 testing solutions. It discusses the challenges posed by the Omicron variant and the industry's response, including the shift towards rapid antigen tests. The impact of the pandemic on healthcare systems and other therapies is examined, along with Roche's Alzheimer's drug development strategy. The conversation highlights lessons learned from the pandemic, emphasizing innovation, partnerships, and diversity in clinical trials.

How does Roche plan to approach Alzheimer's drug development differently than Biogen?

What silver linings have emerged from the pandemic for the healthcare industry?

What lessons has Roche learned from the pandemic regarding innovation?